The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases
Study Details
Study Description
Brief Summary
The aim of the study is to assess the role of statins and different dosage regimens in the prevention of contrast-induced acute kidney injury in patients with cardiovascular diseases requiring intravenous contrast media administration before computer tomography
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Placebo Comparator: Control group No statins being used for prevention |
Drug: Atorvastatin
To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
|
Active Comparator: Low-dose statin therapy Atorvastatin 40 mg |
Drug: Atorvastatin
To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
|
Active Comparator: High-dose statin therapy Atorvastatin 80 mg |
Drug: Atorvastatin
To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
|
Outcome Measures
Primary Outcome Measures
- Contrast-induced acute kidney injury [48-72 hours after contrast media administration]
CI-AKI is defined as the 25% rise (or 0,5 mg/dl) of serum creatinine from baseline assessed 48 hours after administration of contrast media.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent
-
Indications for computer tomography with intravenous contrast media administration
-
Cardiovascular diseases (arterial hypertension, arrhythmia etc)
Exclusion Criteria:
-
Pregnancy
-
Statin therapy before inclusion in the study
-
Acute coronary syndromes
-
Contraindications for statins administration
-
Patients with chronic kidney disease stages 4-5
-
Contraindications for computer tomography with contrast media administration
-
Nephrotoxic drugs use (NSAIDS, vancomycin etc)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sechenov University | Moscow | Russian Federation |
Sponsors and Collaborators
- I.M. Sechenov First Moscow State Medical University
Investigators
- Principal Investigator: Olga Mironova, MD PhD, Sechenov University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 09/2020